Literature DB >> 36238449

Applying stem cell therapy in intractable diseases: a narrative review of decades of progress and challenges.

Anna Pick Kiong Brianna1, Ying Pei Ling1.   

Abstract

Background and Objective: Stem cell therapy (SCT) is one of the vastly researched branches of regenerative medicine as a therapeutic tool to treat incurable diseases. With the use of human stem cells such as embryonic stem cells (ESCs), adult stem cells (ASCs) and induced pluripotent stem cells (iPSCs), stem cell therapy aims to regenerate or repair damaged tissues and congenital defects. As stem cells are able to undergo infinite self-renewal, differentiate into various types of cells and secrete protective paracrine factors, many researchers have investigated the potential of SCT in regenerative medicine. Therefore, this review aims to provide a comprehensive review on the recent application of SCT in various intractable diseases, namely, haematological diseases, neurological diseases, diabetes mellitus, retinal degenerative disorders and COVID-19 infections along with the challenges faced in the clinical translation of SCT.
Methods: An extensive search was conducted on Google scholar, PubMed and Clinicaltrials.gov using related keywords. Latest articles on stem cell therapy application in selected diseases along with their challenges in clinical applications were selected. Key content and findings: In vitro and in vivo studies involving SCT are shown to be safe and efficacious in treating various diseases covered in this review. There are also a number of small-scale clinical trials that validated the positive therapeutic outcomes of SCT. Nevertheless, the effectiveness of SCT are highly variable as some SCT works best in patients with early-stage diseases while in other diseases, SCT is more likely to work in patients in late stages of illnesses. Among the challenges identified in SCT translation are uncertainty in the underlying stem cell mechanism, ethical issues, genetic instability and immune rejection. Conclusions: SCT will be a revolutionary treatment in the future that will provide hope to patients with intractable diseases. Therefore, studies ought to be done to ascertain the long-term effects of SCT while addressing the challenges faced in validating SCT for clinical use. Moreover, as there are many studies investigating the safety and efficacy of SCT, future studies should look into elucidating the regenerative and reparative capabilities of stem cells which largely remains unknown. 2022 Stem Cell Investigation. All rights reserved.

Entities:  

Keywords:  Stem cell therapy (SCT); applications; challenges; clinical translation; stem cells

Year:  2022        PMID: 36238449      PMCID: PMC9552054          DOI: 10.21037/sci-2022-021

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  191 in total

1.  Embryonic stem cell trials for macular degeneration: a preliminary report.

Authors:  Steven D Schwartz; Jean-Pierre Hubschman; Gad Heilwell; Valentina Franco-Cardenas; Carolyn K Pan; Rosaleen M Ostrick; Edmund Mickunas; Roger Gay; Irina Klimanskaya; Robert Lanza
Journal:  Lancet       Date:  2012-01-24       Impact factor: 79.321

2.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

3.  Evaluation of Transplanted Autologous Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in Exudative Age-Related Macular Degeneration.

Authors:  Seiji Takagi; Michiko Mandai; Kiyoko Gocho; Yasuhiko Hirami; Midori Yamamoto; Masashi Fujihara; Sunao Sugita; Yasuo Kurimoto; Masayo Takahashi
Journal:  Ophthalmol Retina       Date:  2019-04-26

Review 4.  Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.

Authors:  Yong Fan; Shi-Yan Ng
Journal:  Transl Neurodegener       Date:  2020-01-07       Impact factor: 8.014

5.  Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models.

Authors:  Kari Pollock; Heather Dahlenburg; Haley Nelson; Kyle D Fink; Whitney Cary; Kyle Hendrix; Geralyn Annett; Audrey Torrest; Peter Deng; Joshua Gutierrez; Catherine Nacey; Karen Pepper; Stefanos Kalomoiris; Johnathon D Anderson; Jeannine McGee; William Gruenloh; Brian Fury; Gerhard Bauer; Alexandria Duffy; Theresa Tempkin; Vicki Wheelock; Jan A Nolta
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

6.  Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model.

Authors:  Mahesh Khatri; Levi Arthur Richardson; Tea Meulia
Journal:  Stem Cell Res Ther       Date:  2018-01-29       Impact factor: 6.832

Review 7.  Ethical and Safety Issues of Stem Cell-Based Therapy.

Authors:  Vladislav Volarevic; Bojana Simovic Markovic; Marina Gazdic; Ana Volarevic; Nemanja Jovicic; Nebojsa Arsenijevic; Lyle Armstrong; Valentin Djonov; Majlinda Lako; Miodrag Stojkovic
Journal:  Int J Med Sci       Date:  2018-01-01       Impact factor: 3.738

8.  Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection.

Authors:  Thomas L Williams; Maria T Colzani; Robyn G C Macrae; Emma L Robinson; Stuart Bloor; Edward J D Greenwood; Jun Ru Zhan; Gregory Strachan; Rhoda E Kuc; Duuamene Nyimanu; Janet J Maguire; Paul J Lehner; Sanjay Sinha; Anthony P Davenport
Journal:  Commun Biol       Date:  2021-07-29

9.  Derivation of pluripotent epiblast stem cells from mammalian embryos.

Authors:  I Gabrielle M Brons; Lucy E Smithers; Matthew W B Trotter; Peter Rugg-Gunn; Bowen Sun; Susana M Chuva de Sousa Lopes; Sarah K Howlett; Amanda Clarkson; Lars Ahrlund-Richter; Roger A Pedersen; Ludovic Vallier
Journal:  Nature       Date:  2007-06-27       Impact factor: 49.962

10.  Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.

Authors:  Jun Wu; Dingyun Song; Zhongwen Li; Baojie Guo; Yani Xiao; Wenjing Liu; Lingmin Liang; Chunjing Feng; Tingting Gao; Yanxia Chen; Ying Li; Zai Wang; Jianyan Wen; Shengnan Yang; Peipei Liu; Lei Wang; Yukai Wang; Liang Peng; Glyn Nigel Stacey; Zheng Hu; Guihai Feng; Wei Li; Yan Huo; Ronghua Jin; Ng Shyh-Chang; Qi Zhou; Liu Wang; Baoyang Hu; Huaping Dai; Jie Hao
Journal:  Cell Res       Date:  2020-06-16       Impact factor: 46.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.